DR not main cause of blindness in diabetics

Article

Diabetic retinopathy (DR) is not the leading cause of ocular co-morbidity in diabetic subjects, according to a study published in the June 2008 issue of the British Journal of Ophthalmology.

Diabetic retinopathy (DR) is not the leading cause of ocular co-morbidity in diabetic subjects, according to a study published in the June 2008 issue of the British Journal of Ophthalmology.

Peter H. Scanlon, MBBS, MD, FRCP, DCH, DRCOG, DO, MRCOphth of Cheltenham General Hospital and colleagues conducted slip-lamp biomicroscopy examinations on diabetic subjects (n=1549) following assessment of best corrected visual acuity (BCVA) by a standardized logarithm of minimum angle resolution (logMAR).

The researchers found subnormal vision (logMAR ≥0.3) in 9.0% of subjects; blindness (logMAR ≥1.3), in 0.45%. For any given eye, sensitivity of subnormal vision was 33.4%, specificity was 85.9%, positive status was 18.6% and negative status was 93.0% predictive of DR. Lenticular opacity, macular degeneration, diabetic maculopathy, other media causes including corneal opacity, and amblyopia were found to be contributory causes of moderate visual loss (logMAR 0.50–0.98) or acuity blindness (logMAR ≥1.0) in 49%, 29%, 15%, 13% and 10% of subjects, respectively.

The researchers concluded that BCVA in isolation is not a reliable indicator of DR, and that DR is not the primary cause of vision loss in diabetic subjects.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.